إعلان
إعلان

GLMD

GLMD logo

Galmed Pharmaceuticals Ltd.

0.84
USD
برعاية
-0.01
-0.93%
٠٩ يناير, ١٥:١٢ UTC -5
مغلق
exchange

بعد الإغلاق

0.84

0.00
0.00%

تقارير أرباح GLMD

النسبة الإيجابية المفاجئة

GLMD تفوق 23 من 36 آخر التقديرات.

64%

التقرير التالي

بيانات التقرير القادم
٣١ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.52
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+57.58%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
--

Galmed Pharmaceuticals Ltd. earnings per share and revenue

On ٢٦ نوفمبر ٢٠٢٥, GLMD reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.55 USD, resulting in a 40.09% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +12.40% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 المحللين forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an زيادة of 57.58% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Galmed Pharmaceuticals Ltd. reported EPS of -$0.33, beating estimates by 40.09%, and revenue of $0.00, -- -- expectations.
The stock price moved up 12.4%, changed from $0.82 before the earnings release to $0.92 the day after.
The next earning report is scheduled for ٣١ مارس ٢٠٢٦.
Based on 3 المحللين, Galmed Pharmaceuticals Ltd. is expected to report EPS of -$0.52 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان